Fount of Information

AcroBiosystems社 【Inspiring Target】CXCR4 and CCR5, Promising Targets for HIV and Tumor Therapy

この製品に関するご意見・ご照会・お問合せはこちら

Comprehensive_ADC_target_1.png CAREER.pngJOIN US
   
Products Support Resources Insights About Us

 

【Inspiring Target】CXCR4 and CCR5, Promising Targets for HIV and Tumor Therapy

  


 

News Expressed

  

On February 15, 2022, the third case in the world who achieved long-term remission of AIDS - "New York patient" appeared. At the 29th Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, USA, a research team from Weill Cornell Medical College reported a case: a New York City patient with HIV and acute myeloid leukemia (AML) has become the world's first woman and third person to be cured from AIDS to date. The patient had received CCR5 Δ32/Δ32 stem cell transplantation from a donor who is naturally resistant to HIV.

 

Even though HIV is a multifactorial disease, studies have shown that specific targeting of CXCR4 and CCR5 is a promising therapeutic strategy for HIV as well as other immune conditions such as tumors.

 

Read_Full_Text.PNG

 

ACROBiosystems is focused on overcoming the challenges during the preparation of GPCRs. We provide full-length GPCRs proteins via "FLAG" technology platforms to assist our customers and collaborators with antibody drugs and therapeutic strategies. Recently, full-length CCR5 and CXCR4 proteins have been developed and launched, do not hesitate to consult and order. 

 

GPCRs.jpg

  


  

Product List

 

List.png 

Product Features

 

  • Full-length CCR5 and CXCR4 proteins are with native and complete conformation

 

  • Higher immunogenicity due to inherent characteristics of VLP

 

  • High biological activity is verified by binding to antibodies

  

  • 100-300 nm in size and high identity verified by DLS, can be used as an optimal target for dendritic cells and phage display

 

  • Suitable for immunization/ELISA/SPR/BLI/cell experiment etc.

  


 

Full-length CCR5-VLP Protein (Cat. No. CC5-H52P3)

 

>> High bioactivity

 

QC_tested.jpg

  

Immobilized Human CCR5 Full-Length Protein-VLP (Cat. No. CC5-H52P3) at 2 μg/mL (100 μL/well) can bind Anti-Human CCR5 Antibody, Mouse IgG2a with a linear range of 2-78 ng/mL (QC tested).

 

Request_For.PNG

 

>> High identity

 

DSL_result.jpg 

The mean peak Radius of VLP is 130-170 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

 


 

Full-length CXCR4 Protein-VLP Protein (Cat. No. CX4-H5219)

 

>> High bioactivity

 

QC_tested2.jpg 

Immobilized Human CXCR4 Full-Length Protein-VLP (Cat. No. CX4-H5219) at 5 μg/mL (100 μL/well) can bind Human ulocuplumab, Human IgG4 with a linear range of 1-31 ng/mL (QC tested).

 

Request_For.PNG

 

>> High identity

 

DSL_result2.jpg

 

The mean peak Radius of VLP is 110-170 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

  


 

>> Learn more about FLAG: multi-pass transmembrane proteins and technology platforms

 

FLAG.jpg

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。